title: [Therapeutic activity of gemcitabine in intracranial tumors].
abstract: Gemcitabine is known to exert a therapeutic effect on brain tumors despite the limited permeability of the blood-brain barrier (BBB). In our experimental research single intraperitoneal (i.p.) injection of gemcitabine 25 mg/kg provided increase in median survival of mice with intracranially transplanted Ehrlich carcinoma by 41-89% (p < 0.001). In this experimental model i.p. administration of gemcitabine (permeability of the BBB of less than 10%), carmustine (good permeability of the BBB), cyclophosphamide (poor permeability of the BBB) and cisplatin (doesn't penetrate through the BBB) increased median survival of mice by 88% (p < 0.001), 59% (p = 0.001), 35% (p = 0.005) and 18% (p = 0.302) respectively. Considering strong correlation between antitumor activity of the drugs (carmustine, cyclophosphamide and cisplatin) and their permeability of the BBB, efficacy of gemcitabine in intracranial tumors could be due to its wide range of therapeutic doses.
authors.forename: A N
authors.initials: AN
authors.lastname: Stukov
authors.forename: L V
authors.initials: LV
authors.lastname: Filatova
authors.forename: D Kh
authors.initials: DKh
authors.lastname: Latipova
authors.forename: V G
authors.initials: VG
authors.lastname: Bespalov
authors.forename: O A
authors.initials: OA
authors.lastname: Belyaeva
authors.forename: G S
authors.initials: GS
authors.lastname: Kireeva
authors.forename: I N
authors.initials: IN
authors.lastname: Vasilieva
authors.forename: V A
authors.initials: VA
authors.lastname: Alexandrov
authors.forename: M A
authors.initials: MA
authors.lastname: Maidin
authors.forename: A L
authors.initials: AL
authors.lastname: Semenov
authors.forename: S F
authors.initials: SF
authors.lastname: Vershinina
authors.forename: A B
authors.initials: AB
authors.lastname: Markochev
authors.forename: N Kh
authors.initials: NKh
authors.lastname: Abduloeva
authors.forename: V A
authors.initials: VA
authors.lastname: Chubenko
authors.forename: T Yu
authors.initials: TY
authors.lastname: Semiglazova
mesh_terms: D000818:Animals; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000494:pharmacology*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology*; D001812:Blood-Brain Barrier / Q000187:drug effects / Q000378:metabolism; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000209:etiology; D002286:Carcinoma, Ehrlich Tumor / Q000188:drug therapy*; D002330:Carmustine / Q000008:administration & dosage; D002945:Cisplatin / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D007274:Injections, Intraperitoneal; D008297:Male; D051379:Mice; D009368:Neoplasm Transplantation; D000093542:Gemcitabine
chemical_list: D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D003520:Cyclophosphamide; D002945:Cisplatin; D002330:Carmustine; D000093542:Gemcitabine